Welcome to the official website of the Ethypharm Group. This website is regulated by the Code of Best Practices of the International Federation of Pharmaceutical Manufacturers. Some information on this site may not be in conformity with French regulations on advertising. By continuing your navigation, you accept this website's use of cookies.

Our history

Established in 1977, Ethypharm became rapidly a major player in the field of Drug Delivery Systems.

For over 30 years Ethypharm was developing and manufacturing products sold by pharmaceutical partners around the world.

In the recent years, the Company took a new turning point by marketing directly to prescribers and patients its pharmaceutical products.

ETHYPHARM IN A NUTSHELL

FROM 1977 TO 2000

The Drug Delivery Years.
Ethypharm created numerous Business Partners worldwide.

THE YEARS 2000 TO 2013

A focused strategy to specialise in the pain and addiction field.

SINCE 2014

Ethypharm commences the direct marketing of its products
by founding its own commercial structures in Europe.

 

1977-2000: THE DDS YEARS

Established in 1977, within a few years Ethypharm became one of the European Leaders in drug delivery and oral modified release formulations (e.g. extended-release micro-granules, orodispersible tablets, and improved bioavailability formulations).

Ethypharm developed with partners or under its own technologies, new formulations adapted to the life cycle management of products. These products were then commercialised by its Partners.

Ethypharm rapidly expanded its partnerships to the international markets in Europe, then in North America and in China.

Key products & stages

1980

Launch of Extended-Release Diltiazem

1983

Launch of Fenofibrate

1993

Launch of Extended-Release Morphine

1996

Creation of Chinese subsidiary

1999

Acquisition of Prographarm Laboratoire

2000-2014: PARTNERED SALES

Ethypharm concentrates on the development of its own products and deepens progressively its expertise in the fields of pain and addiction. It retains the Partnership model as the means of marketing.

Ethypharm continues its development of pharmaceutical products destined for the generic market, based on its own technologies.

Key products & stages

2004

Launch of Omeprazole

2006

Launch of Buprenorphine in France

2008

Launch of Orodispersible Oxycodone in Europe

2011

Launch of Esomeprazole generic in Europe
and of Buprenorphine in United States

2014

Launch of Fentanyl SL in Europe
Launch Oxycodone LP in Canada

2015

Creation of Laboratoires Ethypharm

2016

Creation of Ethypharm UK

2017

Acquisition of Martindale Pharma in The United Kingdom

TODAY ETHYPHARM IS CLOSER THAN EVER TO THE PATIENTS

In the recent years, the Company built its own commercial structures and brings its products  directly to prescribers and patients.

We promote open innovation and our teams are constantly going out, seeing clinicians, attending to conferences, meeting people and patients to understand and face up to the outside world to foster new ideas.

 

 

A Group specialising in the field of pain, opioid addiction, emergency care and sterile injectables

To follow its strategy of becoming a European speciality based pharmaceutical company, Ethypharm acquired Martindale Pharma on February 2017. Martindale Pharma is a leading UK-based speciality pharmaceutical company providing essential medicines to over 50 countries around the world. The company specialises in the field of opioid addiction, emergency care and sterile injectables.

By clicking on this link, you agree to leave our website.
Are you sure?
NO     YES